Published in Transl Res on July 19, 2011
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc Res (2016) 0.79
PCSK9 and triglyceride-rich lipoprotein metabolism. J Biomed Res (2015) 0.79
Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovasc Res (2016) 0.75
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 19.28
The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatry (1971) 9.16
A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet (2006) 7.89
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 5.65
PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res (2008) 3.92
The LDL receptor. Arterioscler Thromb Vasc Biol (2009) 3.78
Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci (2007) 3.59
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 2.89
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 2.76
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med (1995) 2.26
Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med (2005) 2.14
Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology (2008) 2.07
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem (2007) 1.84
Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol (2010) 1.68
Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res (2002) 1.67
Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem (2008) 1.56
Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy. J Cardiometab Syndr (2007) 1.55
Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat (2005) 1.54
Reproducibility of stable isotope-labeled tracer measures of VLDL-triglyceride and VLDL-apolipoprotein B-100 kinetics. J Lipid Res (2007) 1.37
Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun (2007) 1.27
Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol (2011) 1.24
Reproducibility of glucose, fatty acid and VLDL kinetics and multi-organ insulin sensitivity in obese subjects with non-alcoholic fatty liver disease. Int J Obes (Lond) (2010) 1.18
PCSK9: an enigmatic protease. Biochim Biophys Acta (2008) 1.02
Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology (2006) 1.00
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis (2010) 0.95
Microbial ecology: human gut microbes associated with obesity. Nature (2006) 36.98
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
Molecular mediators of hepatic steatosis and liver injury. J Clin Invest (2004) 9.40
A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med (2003) 9.23
Human fatty liver disease: old questions and new insights. Science (2011) 8.03
Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med (2004) 6.12
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem (2002) 5.89
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Physical frailty and body composition in obese elderly men and women. Obes Res (2004) 4.61
Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A (2004) 4.60
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A (2008) 4.57
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A (2005) 4.56
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes (2007) 4.28
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Aging, adiposity, and calorie restriction. JAMA (2007) 3.95
Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem (2004) 3.93
Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest (2002) 3.85
Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med (2010) 3.73
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest (2006) 3.54
Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci U S A (2004) 3.54
Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes (2008) 3.47
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem (2007) 3.45
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet (2006) 3.38
A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature (2012) 3.35
Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr (2005) 3.33
Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol (2006) 3.29
Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology (2008) 3.04
Metabolic and structural effects of phosphatidylcholine and deoxycholate injections on subcutaneous fat: a randomized, controlled trial. Aesthet Surg J (2013) 3.02
Assessing adiposity: a scientific statement from the American Heart Association. Circulation (2011) 3.00
Effect of weight loss and exercise on frailty in obese older adults. Arch Intern Med (2006) 2.94
Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell (2008) 2.87
Effect of lifestyle intervention on metabolic coronary heart disease risk factors in obese older adults. Am J Clin Nutr (2006) 2.76
LXRs regulate the balance between fat storage and oxidation. Cell Metab (2005) 2.75
Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation (2004) 2.73
Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res (2005) 2.72
Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest (2004) 2.66
Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr (2006) 2.57
Energy balance and its components: implications for body weight regulation. Am J Clin Nutr (2012) 2.51
Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A (2008) 2.42
Bone mineral density response to caloric restriction-induced weight loss or exercise-induced weight loss: a randomized controlled trial. Arch Intern Med (2006) 2.37
One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol A Biol Sci Med Sci (2006) 2.31
Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology (2007) 2.29
Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes (2013) 2.25
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr (2012) 2.23
Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest (2012) 2.19
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology (2009) 2.19
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010) 2.10
Schoenheimer effect explained--feedback regulation of cholesterol synthesis in mice mediated by Insig proteins. J Clin Invest (2005) 2.03
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. Hum Mol Genet (2008) 1.98
Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res (2008) 1.98
Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res (2002) 1.97
Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem (2007) 1.97
Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab (2009) 1.95
WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinformatics (2006) 1.95
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab (2008) 1.94
Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab (2012) 1.93
Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91
Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am J Physiol Endocrinol Metab (2007) 1.85
TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes (2009) 1.83
The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab (2012) 1.79
Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. Cell Metab (2009) 1.79
Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology (2006) 1.75
Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am J Clin Nutr (2006) 1.75
Effects of supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans. Am J Clin Nutr (2012) 1.71
Lower extremity muscle size and strength and aerobic capacity decrease with caloric restriction but not with exercise-induced weight loss. J Appl Physiol (1985) (2006) 1.68
Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res (2002) 1.67
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc (2006) 1.66
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem (2009) 1.65
Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab (2006) 1.64
Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry (2004) 1.63
Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J Biol Chem (2002) 1.63
Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care (2013) 1.63
Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology (2010) 1.62
Energy expenditure, sex, and endogenous fuel availability in humans. J Clin Invest (2003) 1.62
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res (2008) 1.61
The fatty acid translocase gene CD36 and lingual lipase influence oral sensitivity to fat in obese subjects. J Lipid Res (2011) 1.60
Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation (2011) 1.59
Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production. Age (Dordr) (2009) 1.57
Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology (2013) 1.57
What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean? Diabetes (2003) 1.56
Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy. J Cardiometab Syndr (2007) 1.55
Bone mineral density improvement after lung volume reduction surgery for severe emphysema. Chest (2005) 1.53